SCHEMBL22490239

SCHEMBL22490239

Cc1ccc(C(=O)Nc2ccn(C)n2)cc1Br

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.66
RAB9A P51151 6/20 0.66
MTOR P42345 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.47
HPGDS O60760 1/20 0.46
GRM5 P41594 1/20 0.46
RPS6KA3 P51812 1/20 0.46
RPS6KA2 Q15349 1/20 0.46
HPGD P15428 2/20 0.46
MAPK1 P28482 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21590291 0.81 NPC1 (0.75) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL23884739 0.76 NPC1 (0.71) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL12579391 0.76 NPC1 (0.58) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL2667078 0.76 NPC1 (0.66) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL22490159 0.75 MTOR (0.44) NPC1RAB9AMTORSMN1; SMN2LMNA
SCHEMBL1376302 0.75 NPC1 (0.74) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL12579765 0.75 NPC1 (0.75) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL9991288 0.75 NPC1 (0.60) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL1800369 0.75 GRM5 (0.63) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL9989116 0.74 NPC1 (0.60) NPC1RAB9ASMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020198053-A1 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-10-01 WO disclosed